TY - JOUR
T1 - The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without variable region of the heavy immunoglobulin chain bias
AU - Lim, Annick
AU - Luderschmidt, Stephan
AU - Weidinger, Anke
AU - Schnopp, Christina
AU - Ring, Johannes
AU - Hein, Rüdiger
AU - Ollert, Markus
AU - Mempel, Martin
N1 - Funding Information:
Supported by grants from the DFG (Me 1798/2-1), the BMBF (01GC0104 to MM, JR, and MO), the Galderma Foundation (MM), and the KKF University Hospital “Rechts der Isar,” Technical University Munich.
PY - 2007/9
Y1 - 2007/9
N2 - Background: Patients with atopic diseases are characterized by high levels of specific IgE production. However, little is known about the composition of their B-cell repertoires. Objectives: We sought to analyze the complete PBMC-derived IgE repertoire and to compare clonal expansions between different patients. Methods: We have analyzed the IgE-bearing B-cell receptor repertoire in highly atopic patients (>1000 IU/mL) using quantitative RT-PCR, complementarity determining region 3 spectratyping, and sequence analysis. Three representative patients were additionally followed during anti-IgE therapy. Results: Atopic patients exhibited 100 to 1000 times more IgE-specific transcripts than control individuals. These patients used a variable region of the heavy immunoglobulin chain (VH) ε{lunate} repertoire highly similar to their IgM and IgG repertoires, with preference of VH3b, VH4, VH3a, and VH1 segments. Each patient harbored individual clonal expansions, most probably as correlation of allergen-specific IgE production. Common expansions within the complementary determining region 3 shared by several individuals with similar sensitization patterns were found in spectratyping analysis. However, these antigen-driven expansions showed differences on the sequence level. In omalizumab-treated patients the clinical improvement was paralleled by a clear increase in the ratio of IgG/IgE transcripts. Conclusion: The IgE repertoire in atopic patients follows the VH use patterns seen for other immunoglobulins and seems to preferentially recruit individual rearrangements rather than public expansions. Clinical implications: The detailed analysis of the IgE B-cell repertoire is highly suitable to follow changes in IgE uses during different therapy modalities.
AB - Background: Patients with atopic diseases are characterized by high levels of specific IgE production. However, little is known about the composition of their B-cell repertoires. Objectives: We sought to analyze the complete PBMC-derived IgE repertoire and to compare clonal expansions between different patients. Methods: We have analyzed the IgE-bearing B-cell receptor repertoire in highly atopic patients (>1000 IU/mL) using quantitative RT-PCR, complementarity determining region 3 spectratyping, and sequence analysis. Three representative patients were additionally followed during anti-IgE therapy. Results: Atopic patients exhibited 100 to 1000 times more IgE-specific transcripts than control individuals. These patients used a variable region of the heavy immunoglobulin chain (VH) ε{lunate} repertoire highly similar to their IgM and IgG repertoires, with preference of VH3b, VH4, VH3a, and VH1 segments. Each patient harbored individual clonal expansions, most probably as correlation of allergen-specific IgE production. Common expansions within the complementary determining region 3 shared by several individuals with similar sensitization patterns were found in spectratyping analysis. However, these antigen-driven expansions showed differences on the sequence level. In omalizumab-treated patients the clinical improvement was paralleled by a clear increase in the ratio of IgG/IgE transcripts. Conclusion: The IgE repertoire in atopic patients follows the VH use patterns seen for other immunoglobulins and seems to preferentially recruit individual rearrangements rather than public expansions. Clinical implications: The detailed analysis of the IgE B-cell repertoire is highly suitable to follow changes in IgE uses during different therapy modalities.
KW - B cells
KW - IgE repertoire
KW - atopic eczema
KW - omalizumab
UR - http://www.scopus.com/inward/record.url?scp=34548329663&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2007.05.035
DO - 10.1016/j.jaci.2007.05.035
M3 - Article
C2 - 17631954
AN - SCOPUS:34548329663
SN - 0091-6749
VL - 120
SP - 696
EP - 706
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -